Long-chain fatty acid oxidation changes in a β2 glycoprotein I-induced preeclampsia-like mouse model

Placenta
X DingH Yu

Abstract

Abnormal fatty acid oxidation (FAO) and lipid metabolism have been found related to preeclampsia (PE). Antiphospholipid syndrome (APS) as a clinical risk factor for PE has also been reported with abnormal lipid metabolism. However, the role of FAO in PE accompanied with APS is unknown. We aimed to investigate long-chain FAO changes in a PE-like rodent model induced by beta 2-glycoprotein I (β2GPI). The PE-like model was established by injection of β2GPI (β2GPI group) or normal saline (control group) into C57BL/6J mice which were sacrificed on day 14 or 18 of gestation. Serum levels of anti-cardiolipin antibodies (aCL), anti-β2GPI antibodies (aβ2GPI) and serum lipids were assayed. Lipid deposition in the placenta and maternal liver was detected by lipid staining. Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) mRNA and protein expression in the placenta and maternal liver was analyzed. The β2GPI group showed PE-like symptoms including hypertension, proteinuria and adverse pregnancy outcomes. Serum aCL, aβ2GPI, free fatty acid (FFA) and triglyceride (TG) levels in the β2GPI group were significantly elevated compared with the corresponding control group (P < 0.05), while cholesterol showed no significant changes. Placenta and m...Continue Reading

References

Aug 26, 1999·Rheumatology·E L Radway-BrightD A Isenberg
Jan 12, 2001·Obstetrics and Gynecology·M DreyfusJ L Pasquali
Apr 17, 2001·American Journal of Obstetrics and Gynecology·D W BranchUNKNOWN National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network
Nov 7, 2002·JAMA : the Journal of the American Medical Association·Zi YangJamal A Ibdah
Jan 14, 2005·Annals of the Rheumatic Diseases·D Le Thi ThuongJ-C Piette
Dec 20, 2005·Obstetrical & Gynecological Survey·Sajal GuptaRakesh K Sharma
May 29, 2007·American Journal of Hypertension·Jeffrey GilbertJoey Granger
May 23, 2009·Journal of Hypertension·Nicola J RobinsonIan P Crocker
Jun 6, 2009·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Pia M VillaRisto Kaaja
Aug 12, 2009·Thrombosis Research·Vikki M Abrahams
Feb 6, 2010·American Journal of Reproductive Immunology : AJRI·Melissa J MullaVikki M Abrahams
Jul 6, 2010·Lancet·Eric A P SteegersRobert Pijnenborg
Nov 17, 2010·International Immunopharmacology·Weidong XieGuoping Cai
Dec 21, 2010·Expert Review of Obstetrics & Gynecology·Eric M George, Joey P Granger
Mar 4, 2011·Seminars in Thrombosis and Hemostasis·Lothar HeilmannJawed Fareed
Jul 4, 2012·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·Adrienne Carruth GriffinLinda M Ernst

❮ Previous
Next ❯

Citations

Dec 20, 2015·American Journal of Reproductive Immunology : AJRI·Lena ErlandssonStefan R Hansson
Feb 18, 2016·Reproduction : the Official Journal of the Society for the Study of Fertility·Priyadarshini PanthamLawrence W Chamley
Mar 18, 2017·Clinical Science·Anjali ChauhanLouise D McCullough

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.